Medtronic plc has won FDA clearance for its Cardioinsight noninvasive 3-D mapping system. The device, which has been approved in Europe for nearly five years, is used to improve the mapping of electrical disorders of the heart. The Dublin-based company first gained access to the device through its $93 million acquisition of Cleveland-based Cardioinsight Inc. (See Medical Device Daily, June 22, 2015.)